Trial Profile
Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Berzosertib (Primary) ; Gemcitabine
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 14 Jul 2023 Planned End Date changed from 22 Mar 2023 to 12 Aug 2024.
- 06 Jun 2023 Status changed from active, no longer recruiting to completed according to result presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results of final overall survival (OS) and biomarker analyses presented at the 59th Annual Meeting of the American Society of Clinical Oncology